As a sector closely pertinent to people’s livelihood, the life science sector has always been, and will continue to be, a focus of China’s antitrust enforcement. In 2018, China’s public antitrust enforcement entered into a transitional period due to the internal institutional reform, which will remodel China’s antitrust enforcement regime with a series of significant changes to take place. This article highlights the major changes brought by the institutional reform and examines various types of high-profile antitrust cases in the life science sector. For multinational companies conducting business in the life science sectors, we have also predicted China’s antitrust trends in terms of pay-for-delay agreements, generic drug-related practices, and follow-on actions.
